Villeda-Sandoval CI, González-Cuenca E, Sotomayor-de Zavaleta M, Feria-Bernal G, Calao-Pérez MB, Ibarra-Saavedra R, Quijada-Carlton H, Castillejos-Molina RA

Language: Spanish
References: 11
Page: 250-255
PDF size: 243.19 Kb.

ABSTRACT

Background: The use of phosphodiesterase-5 inhibitors (PPD-5Is) and other sexual function enhancers is a frequent practice among men presenting with erectile dysfunction. Aims: The aim of our study was to determine the frequency of recreational use of these substances in a Mexican population sample.
Methods: An observational, cross-sectional, and descriptive study was conducted. The “Male Urologic Health” survey and the International Index of Erectile Function (IIEF- 5) were applied to male volunteers between the ages of 18 and 50 years. The variables analyzed were demographic, clinical, and pertaining to behavior in relation to enhancers for improving sexual function.
Results: A total of 373 surveys were obtained and 271 subjects with an active sex life were analyzed. The mean age was 34 years (20 to 49 year range) and the mean BMI was 26.3 kg/m² (17.7 to 42.5 range). Thirteen men (4.8%) reported the recreational use of enhancers. The most frequent motive for their use was to have greater confidence in achieving erection. The most widely used PPD-5Is were vardenafil (7/13) and tadalafil (5/13). The men that used these substances had an earlier onset of sexual activity, more sexual partners, and the majority of them were in a stable relationship.
Conclusions: The prevalence of the use of sexual enhancers in the Mexican population is lower than that described in the medical literature.

REFERENCES

1. Aldridge J, Measham F. Sildenafil (Viagra) is used as a reacreational drug in England. BMJ 1999;318(7184):669.

2. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc (2003) 2005;45(1):63-72.

3. McCambridge J, Mitcheson L, Hunt N, et al. The rise of viagra among British illicit drug users: 5-year survey data. Drug Alcohol Rev 2006;25(2):111-113.

4. Rosen RC, Capelleri JC, Smith MD. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11(6):319-326.

5. Korkes F, Costa-Matos A, Gasperini R, et al. Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. J Sex Med 2008;5(10):2414-2418.

6. Musacchio NS, Hartrich M, Garofalo R. Erectile dysfunction and viagra use: what’s up with college-age males? J Adolesc Health 2006;39(3):452-454.

7. Bechara A, Casabé A, De Bonis W, et al. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. J Sex Med 2010;7(11):3736-3742.

8. Harte CB, Meston CM. Recreational use of erectile dysfunction medications in undergraduate men in the United States: characteristics and associated risk factors. Arch Sex Behav 2011;40(3):597-606.

9. Kim AA, Kent CK, Klausner JD. Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra. AIDS 2002;16(10):1425-1428.

10. Sherr L, Bolding G, Maguire M, et al. Elford J. Viagra use and sexual risk behavior among gay men in London. AIDS 2000;14(13):2051-2053.

11. Mondaini N, Ponchietti R, Muir GH, et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce postorgasmic refractory time. Int J Impot Res 2003;15(3):225-228.